True North Therapeutics scores $35 mln Series B
San Francisco-based biotech company True North Therapeutics has closed $35 million in Series B funding. OrbiMed led the round with participation from return backers Kleiner Perkins Caufield & Byers, MPM Capital, SR One and Baxter Ventures.
7 April 2015•4 mins read
